Seprase (FAP)-Targeted RDC Development
Seprase (FAP)-targeted radionuclide drug conjugates are a growing trend in the development of bioconjugated drugs with a wide range of applications in both clinical diagnosis and therapeutics. Alfa Cytology is committed to the development of seprase (FAP)-targeted RDC and possesses a professional RDC development platform, offering high-quality cost-effective services throughout the seprase (FAP)-targeted RDC development process.
Introduction to Seprase (FAP)-Targeted Radionuclide Drug Conjugate (RDC)
Seprase (FAP)-targeted radionuclide drug conjugates (RDCs) present the latest innovations in targeted nuclear therapy. Seprase (FAP)-targeted RDCs can identify and target tumor-associated fibroblasts within the tumor microenvironment. With a high expression of seprase (FAP) across many cancers, seprase (FAP)-targeted RDCs precisely locate and dose therapeutic radiation into target cells. The accrued treatment precision in turn enhances efficacy and curbs side effects, presenting a very promising approach for personalized cancer therapy.
Fig. 1 Schematic structure of Radionuclide-drug conjugate (RDC).
These sophisticated RDCs are composed of key elements, including radioisotopes, chelators, linkers, and targeting moieties, and hold promise as valuable tools for early tumor diagnosis, effective treatment, and thorough postoperative evaluation.
- Radionuclide: This term refers to the radioactive element that emits radiation powerful enough to destroy cancer cells. It emits particles or rays that can aid in the diagnosis of the condition while also providing clinical benefits.
- Chelator: The chelator plays a role in attaching the radionuclide stably, ensuring that only diseased cells are delivered, thereby sparing the normal tissues from exposure.
- Linker: The linker is something that closes the gap between the targeting molecule and the chelator and hence the radionuclide. The safe nature, as well as stability of the RDC, is significantly reliant on the linker, which thus tends to employ the noncleavable types to enhance safety.
- Targeting Molecule: As a homing device, this molecule identifies and attaches to diseased cells. It can be a peptide, antibody, or another substance with a high receptor affinity in the targeted disease cell.
Development of Seprase (FAP)-Targeted Radionuclide Drug Conjugate (RDC)
The following are radionuclide drug conjugate (RDC) development that target fibroblast activation protein seprase (FAP), including but not limited to:
| Name | Indication | Company | Phase |
|---|---|---|---|
| 177Lu-FAP-2286 | Solid Tumors | Novartis | Phase II |
| 68Ga-FAPI-46 | Fibrotic disease; Inflammation; PPET Diagnosis | Ge Healthcare; SOFIE | Phase III |
| 68Ga-NeoBOMB1 | Solid Tumors | Advanced Accelerator Applications SA，National Center for Scientific Research Demokritos | Phase III |
Disclaimer: Alfa Cytology focuses on providing preclinical research service. This table is for information exchange purposes only. This table is not a treatment plan recommendation. For guidance on treatment options, please visit a regular hospital.
Our Services
A novel class of radiopharmaceuticals currently in development, seprase (FAP)-targeted radionuclide drug conjugates (RDCs) are at the forefront in treating several ailments. Alfa Cytology is dedicated to the design and optimization of the choice of any RDC, and more than a one-stop RDC development service can be given for the project.
Innovative Solutions
In responding to the research and development demands presented by the seprase (FAP)-targeted RDC development, two main service areas have been defined: therapeutically-focused radioligand therapy development and theranostic radiopharmaceuticals development.
Diverse Molecular Types
In addition, to satisfy varying targeting demands, our service is further arranged into multiple development routes to cater to the redoubtable diversity of molecular targets and conditions of use.
Small-Molecule Radionuclide Conjugate (SMRC)
Antibody Radionuclide Conjugate (ARC)
Peptide Radionuclide Conjugate (PRC)
It is noteworthy that the current combined application of radionuclide coupled drugs (RDC) and immunotherapy has become an industry hotspot. Our company also provides development services for the combined application of the two.
With the aid of an experienced research team and state-of-the-art equipment, Alfa Cytology will facilitate the seamless scaling of the seprase (FAP)-targeted RDC from drug discovery to preclinical development by really informing you if and how we can help you. For more information or to discuss potential collaborations, please feel free to contact us.
For research use only.